Jonathan Sadeh

968 total citations
20 papers, 705 citations indexed

About

Jonathan Sadeh is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Jonathan Sadeh has authored 20 papers receiving a total of 705 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Rheumatology. Recurrent topics in Jonathan Sadeh's work include Asthma and respiratory diseases (10 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers) and Respiratory and Cough-Related Research (5 papers). Jonathan Sadeh is often cited by papers focused on Asthma and respiratory diseases (10 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers) and Respiratory and Cough-Related Research (5 papers). Jonathan Sadeh collaborates with scholars based in United States, France and United Kingdom. Jonathan Sadeh's co-authors include Paul Stryszak, Paul M. O’Byrne, Mina Gaga, Pascal Chanez, Parameswaran Nair, Khuder Alagha, F.E. Hargreave, Εleftherios Ζervas, H Magnussen and Paresh Soni and has published in prestigious journals such as CHEST Journal, Annals of the Rheumatic Diseases and European Respiratory Journal.

In The Last Decade

Jonathan Sadeh

20 papers receiving 691 citations

Peers

Countries citing papers authored by Jonathan Sadeh

Since Specialization

Citations

This map shows the geographic impact of Jonathan Sadeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Sadeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Sadeh more than expected).

Fields of papers citing papers by Jonathan Sadeh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Sadeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Sadeh. The network helps show where Jonathan Sadeh may publish in the future.

Co-authorship network of co-authors of Jonathan Sadeh

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Sadeh. A scholar is included among the top collaborators of Jonathan Sadeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Sadeh. Jonathan Sadeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes 2020 ·Arthritis Research & Therapy ·Cem Gabay, Gerd R Burmester, Vibeke Strand, Jérôme Msihid, Moshe Zilberstein, Toshio Kimura, Hubert van Hoogstraten, Susan Boklage, Jonathan Sadeh, Neil M.H. Graham, Anita Boyapati	32
2	Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis 2020 ·Arthritis & Rheumatology ·Anita Boyapati, Sergio Schwartzman, Jérôme Msihid, Ernest Choy, Mark C. Genovese, Gerd R Burmester, (unknown), Toshio Kimura, Jonathan Sadeh, David M. Weinreich, George D. Yancopoulos, Neil M.H. Graham	36
3	069 High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response 2019 ·Lara D. Veeken ·Anita Boyapati, Jérôme Msihid, Sergio Schwartzman, Ernest Choy, Gerd R Burmester, (unknown), Toshio Kimura, Jonathan Sadeh, Neil M.H. Graham	5
4	SAT0207 Depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment 2018 ·Annals of the Rheumatic Diseases ·Vibeke Strand, Owen Hagino, (unknown), Susan Boklage, Matthew Reaney, Jonathan Sadeh, (unknown), Erin Mangan, (unknown)	1
5	THU0223 Impact of treatment in patients with rheumatoid arthritis and depressive symptoms in the monarch phase 3 trial of sarilumab 2018 ·Annals of the Rheumatic Diseases ·Vibeke Strand, Owen Hagino, (unknown), Susan Boklage, Matthew Reaney, Jonathan Sadeh, (unknown), Erin Mangan, Tomoatsu Kimura	2
6	Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy 2016 ·Pediatric Research ·Jacob V. Aranda, Charles L. Cai, (unknown), (unknown), Jonathan Sadeh, Gloria B. Valencia, Douglas R. Lazzaro, Kay D. Beharry	36
7	The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects 2016 ·Pulmonary Pharmacology & Therapeutics ·(unknown), Brittany Salter, Desmond M. Murphy, Richard M. Watson, Karen Howie, Joanne Milot, Jonathan Sadeh, Louis‐Philippe Boulet, Paul M. O’Byrne, Gail M. Gauvreau	39
8	Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial 2012 ·Clinical & Experimental Allergy ·Parameswaran Nair, Mina Gaga, Εleftherios Ζervas, Khuder Alagha, F.E. Hargreave, Paul M. O’Byrne, Paul Stryszak, (unknown), Jonathan Sadeh, Pascal Chanez, (unknown)	271
9	Where Are the New Cough Treatments: A Debriefing of Recent Clinical Proof-of-Concept Trials with the NOP Agonist SCH 486757 2011 ·Pharmacology ·Robbie L. McLeod, Deen Tulshian, Jonathan Sadeh	10
10	Quality of Life Following 26 Weeks of Mometasone Furoate/Formoterol Therapy: Results From Two Phase Three Trials in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease 2011 ·CHEST Journal ·Edward Kerwin, Donald P. Tashkin, (unknown), Dennis E. Doherty, Tulin Shekar, (unknown), Jonathan Sadeh	2
11	The Long-term Safety Characteristics of Mometasone Furoate/Formoterol for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease: Pooled Findings From Two 1-Year Multicenter Clinical Trials 2011 ·CHEST Journal ·(unknown), Dennis E. Doherty, Edward Kerwin, Donald P. Tashkin, Tulin Shekar, (unknown), Jonathan Sadeh	2
12	Efficacy and Safety of Mometasone Furoate/Formoterol in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease: Results From Two Phase Three 26-Week Trials 2011 ·CHEST Journal ·Dennis E. Doherty, Donald P. Tashkin, Edward Kerwin, (unknown), Tulin Shekar, (unknown), Jonathan Sadeh	2
13	The Effect of Mometasone Furoate/Formoterol Combination Therapy on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: Results From Two Phase Three Trials in Subjects With Moderate to Very Severe COPD 2011 ·CHEST Journal ·Donald P. Tashkin, Dennis E. Doherty, Edward Kerwin, (unknown), Tulin Shekar, (unknown), Jonathan Sadeh	2
14	Cysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma 2010 ·Respiratory Medicine ·Shamsah Kazani, Jonathan Sadeh, (unknown), Michael E. Wechsler, Elliot Israel	9
15	Treatment With The CXCR2 Antagonist SCH527123 Reduced Neutrophil Levels In Blood And Airways But Not Bone Marrow In Mild Asthmatic Subjects 2010 ·(unknown), Desmond M. Murphy, Richard M. Watson, Karen Howie, Tara X. Strinich, (unknown), (unknown), Kieran J. Killian, (unknown), Jonathan Sadeh, Louis‐Philippe Boulet, Paul M. O’Byrne, Gail M. Gauvreau	7
16	SCH527123, a Novel Treatment Option For Severe Neutrophilic Asthma 2010 ·Mina Gaga, Parameswaran Nair, Frederick E. Hargreave, Jonathan Sadeh, Pascal Chanez	6
17	The Efficacy of a NOP1 Agonist (SCH486757) in Subacute Cough 2009 ·Lung ·Ashley Woodcock, Robbie L. McLeod, Jonathan Sadeh, John A. Smith	33
18	SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects 2009 ·European Respiratory Journal ·Olaf Holz, Sauzanne Khalilieh, Andrea Ludwig-Sengpiel, Henrik Watz, Paul Stryszak, Paresh Soni, Meng‐Han Tsai, Jonathan Sadeh, H Magnussen	150
19	The effect of unfractionated heparin on circulating lymphocyte counts and subsets in humans 2002 ·Thrombosis Research ·Anthony O’Regan, Jonathan Sadeh, Jeffrey S. Berman	2
20	Comparison of three oral appliances for treatment of severe obstructive sleep apnea syndrome 2000 ·Sleep Medicine ·Gabriele Barthlen, Lee K. Brown, (unknown), Jonathan Sadeh, (unknown), Mark C. Zimmerman	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact